A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Study Identifier:
ORIC-944-05
ClinicalTrials.gov Identifier:
NCT07723248
EudraCT Identifier:
N/A
EU CT Number:
2026-525340-15-00
Sponsor:
ORIC Pharmaceuticals
Recruiting

Study Details

Medical Condition
    Study Drug
    • Drug: Rinzimetostat
    • Drug: Darolutamide
    • Drug: Enzalutamide
    • Drug: Docetaxel
    Date
    Jul 2026 - Mar 2028
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    Patient Requirements
    Sex: Male
    Age: 18+ years
    Requirements Information
    Inclusion and Exclusion Criteria
    Inclusion Criteria
    • Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features
    • Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required
    • Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    • Adequate organ function
    Exclusion Criteria
    • Prior treatment for prostate cancer at any stage with cytotoxic chemotherapy, radioligand therapy (ie, 177Lu -PSMA-617, radium-223), ARPIs including apalutamide, darolutamide, and enzalutamide, PARP monotherapy or other systemic anticancer treatment (approved drugs or experimental compounds such as, antibody therapy, immunotherapy, gene or cell therapy, angiogenesis inhibitors, CDK4/6 inhibitors, PRC2 inhibitors) with the following exceptions:
    • Treatment with first-generation antiandrogen agents (eg, bicalutamide, flutamide, nilutamide), but must be discontinued prior to the first dose of study medication
    • Docetaxel treatment is allowed for mCSPC, as long as no signs of failure or disease progression occurred during treatment or within 3 months of treatment completion
    • Any other anticancer therapy (drug or vaccine which does not meet exclusion criterion 1 above) within 28 days or 5 half-lives (whichever is longer) prior to randomization
    • Known or suspected brain metastasis or active leptomeningeal disease
    • Clinically significant cardiovascular disease defined as:
    • Any medical (including active or clinically significant bacterial, fungal, or viral infection) or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the patient inappropriate for the study
    • Active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery are excluded

    Protocol Summary

    Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castration resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate.

    The primary objective of this study is to demonstrate superiority in radiographic progression free survival (rPFS) of the investigational arm of rinzimetostat + darolutamide combination versus physician's choice of control: ARPI (darolutamide or enzalutamide) or docetaxel.

    Trial Locations

    Location
    Status
    Location
    Urology Specialists of the Carolinas - University Place
    Charlotte, North Carolina, United States, 29464
    Status
    Recruiting
    Location
    Summit Urology
    Murray, Utah, United States, 84107
    Status
    Recruiting

    Contact Cure SMA

    User Information

    If you have general questions regarding clinical trials or would like to be added to the Cure SMA mailing list to receive communications regarding future registries, studies, or clinical trials in SMA, please fill out the form below. Fields marked with an asterisk (*) are mandatory.

    • Disability Advocate who does not have SMA
    • I am a healthcare provider
    • I am a researcher
    • I have no direct connection to SMA
    • I have SMA
    • I lost a child to SMA
    • My child has SMA
    • Someone close to me has/had SMA
    • Australia
    • Belgium
    • Brazil
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Estonia
    • France
    • Germany
    • Greece
    • Hong Kong
    • Hungary
    • India
    • Ireland
    • Israel
    • Italy
    • Japan
    • Lebanon
    • Malaysia
    • Mexico
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Puerto Rico
    • Qatar
    • Republic of Korea
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.